Answers are grounded in this paper and cite their sources.
Antimicrobial resistance (AMR) poses a growing global health threat. Nanomedicine, combined with drug repurposing, may help extend the effective lifespan of current and new antimicrobials. This review, presents an Australian perspective on nanotechnology-based therapies, highlighting scientific and clinical challenges. Early consideration of the potential barriers to market access may help to accelerate research translation, regulatory approval and patient access to nano-antimicrobial (NAM) drugs for resistant pathogens, not only in Australia, but globally.
No takes yet. Share an insight, caveat, or question.
Muir et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: